Medicines for T-cell lymphoma: indications, monitoring and treatment at home

An expanding list of drug names is less useful than understanding what a person is taking, why it was selected and how it will be monitored. T-cell lymphoma entities have different evidence bases. The same medicine can also have different status in initial treatment, relapse and maintenance. Approval for one indication does not make a medicine suitable for every T-cell disease or authorise patients to build their own combinations.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

CHOP, CHOEP and BV-CHP contain different components. The last includes brentuximab vedotin within its specified combination. The ESMO–EHA guideline selects treatment by entity, with prior exposure, organ tolerance and purpose also relevant. A medicine absent from the prescription should not be added because it appears in another regimen's abbreviation. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025
Pralatrexate is an antifolate, with particular attention to mucosal symptoms, blood counts and renal function. The US FOLOTYN prescribing information requires folic acid and vitamin B12 support to reduce relevant toxicity and describes monitoring and adjustment. These supplements are part of the treatment arrangement rather than optional wellness products. Confirm timing, route and duration from the individual's prescription. DailyMed: FOLOTYN pralatrexate prescribing information
Separate active from discontinued medicines and preserve the reason for discontinuation. This reduces the chance that a new prescriber unknowingly restarts something associated with a severe reaction. When brand names differ between countries, use the generic name and packaging photographs to help reconcile the list. A change of tablet strength requires a fresh check of tablet numbers rather than reliance on the previous box.

Quick answer

Full guide

A practical medication record includes the generic name, formulation, strength, actual prescription, start and stop dates, reasons for stopping and monitoring requirements. Keep any serious reaction in the record. During transfer to China or return to another country, the phrase “a targeted drug” or an unfamiliar local brand name may not let the receiving team identify an important risk.

Regimen abbreviations do not authorise substitutions

CHOP, CHOEP and BV-CHP contain different components. The last includes brentuximab vedotin within its specified combination. The ESMO–EHA guideline selects treatment by entity, with prior exposure, organ tolerance and purpose also relevant. A medicine absent from the prescription should not be added because it appears in another regimen's abbreviation. d’Amore et al.: ESMO–EHA guideline for peripheral T- and NK-cell lymphomas, 2025

Intravenous treatment and tablets taken at home can belong to the same cycle. NCI explains that administration and recovery schedules differ between regimens. An oral steroid may be intended for a limited set of days, so the dates need to be written down. “Daily” on an incomplete note should not be interpreted as continuing indefinitely. Missed doses, vomiting or inability to swallow require instructions from the prescribing service rather than automatic double dosing. NCI: Chemotherapy to Treat Cancer

Feeling well does not confirm that blood counts or organ function permit the next dose. Hair loss does not prove tumour response. Recording symptoms against drug dates and laboratory results helps the team distinguish toxicity from illness. Dose reduction or interruption should have a documented reason and reassessment plan, rather than depend solely on the patient's impression that day.

Brentuximab vedotin requires the complete CD30-related indication

Brentuximab vedotin is an antibody-drug conjugate, not a general immune-strengthening product. Discussion includes pathology, the systemic or cutaneous entity, prior treatment and the intended combination. Its US label covers several disease settings with different treatment arrangements. A schedule used for another lymphoma cannot be imported into a patient's own prescription simply because the same drug appears. ADCETRIS: current US prescribing information, Pfizer

Report existing numbness, weakness and neurological problems before starting and record new changes during treatment. Infusion reactions, infection and other serious hazards also need monitoring. The US label contraindicates concurrent bleomycin, illustrating why the complete medication list matters. Clinical staff determine whether a symptom requires interruption or adjustment; a patient should not independently proceed with an infusion after a concerning reaction.

China's National Health Commission 2025 guidance separates domestic brentuximab indications from uses in other jurisdictions. If an initial combination is proposed, the hospital should explain its current Chinese-label, guideline and prescribing basis. Availability of a drug and approval of a particular combination are questions that need separate verification. 中国国家卫生健康委：《新型抗肿瘤药物临床应用指导原则（2025年版）》，2026-01-26发布

Chidamide is oral treatment that still requires clinical surveillance

Chidamide is a histone deacetylase inhibitor. Its pivotal phase 2 study evaluated single-agent treatment in Chinese patients with relapsed or refractory PTCL and documented adverse events including reductions in platelets, white cells and neutrophils. Those findings support discussion in the corresponding setting; they do not prove benefit for every individual or superiority of every possible combination. Shi et al.: Chidamide pivotal phase 2 PTCL study, 2015

The National Health Commission guidance lists the PTCL use after at least one previous systemic chemotherapy treatment in relapsed or refractory disease. A separate DLBCL combination and maintenance schedule in the same chapter belongs to a B-cell disease. It must not be copied into a PTCL first-line prescription. Weekly or cycle-based dates deserve particular attention when patients see screenshots of other people's schedules. 中国国家卫生健康委：《新型抗肿瘤药物临床应用指导原则（2025年版）》，2026-01-26发布

Before taking treatment at home, establish when blood counts and other required tests occur, who reviews them and how adjustments are communicated during holidays. Having blood drawn does not mean a clinician has assessed the result. Persistent fatigue, new bleeding or possible infection should not wait until the next supply of tablets arrives.

Golidocitinib needs a prevention and infection-monitoring plan

Golidocitinib is a selective JAK1 inhibitor. JACKPOT8 Part B studied its efficacy and safety in relapsed or refractory PTCL in a single-arm phase 2 trial. A medicine used in rheumatology or dermatology with a similar JAK-related description is not an interchangeable substitute. Drug class alone does not establish the same lymphoma evidence or prescription. Song et al.: JACKPOT8 Part B, phase 2 golidocitinib study

The Chinese National Health Commission guidance identifies conditional approval as monotherapy for adults with relapsed or refractory PTCL after at least one systemic line. It highlights infection, viral reactivation, blood-count and liver monitoring, and Pneumocystis pneumonia prevention during treatment. Ask the team to specify preventive medication and surveillance before a complication develops. 中国国家卫生健康委：《新型抗肿瘤药物临床应用指导原则（2025年版）》，2026-01-26发布

New breathlessness, persistent cough or fever requires reporting. Blurred vision, floaters or declining sight should also prompt contact for assessment. The 2026 maintenance study after first-line response addresses a different research question. The relapsed-disease indication should not be used to assume that every person in a first remission needs the drug added as maintenance. Wei et al.: JACKPOT26 maintenance study, Blood Cancer Journal 2026

Pralatrexate includes prescribed vitamin support

Pralatrexate is an antifolate, with particular attention to mucosal symptoms, blood counts and renal function. The US FOLOTYN prescribing information requires folic acid and vitamin B12 support to reduce relevant toxicity and describes monitoring and adjustment. These supplements are part of the treatment arrangement rather than optional wellness products. Confirm timing, route and duration from the individual's prescription. DailyMed: FOLOTYN pralatrexate prescribing information

Report a sore or ulcerated mouth and difficulty drinking before the next dose. Kidney impairment can increase toxicity, and some common pain medicines and other drugs need an interaction check. Do not independently add anti-inflammatory painkillers or leftover anti-infectives. An overseas label helps identify questions but does not replace review of the actual locally supplied product, nor does it confirm hospital stock.

Mogamulizumab evidence belongs to particular cutaneous entities

Mogamulizumab targets CCR4. MAVORIC randomised patients with previously treated mycosis fungoides or Sézary syndrome. That population limitation matters. A systemic lymphoma somewhere else in the body does not gain the same evidence simply because both diagnoses involve T cells. The full disease and previous treatment should remain visible in a referral. Kim et al.: MAVORIC randomised trial in previously treated MF or Sézary syndrome

The February 2026 US POTELIGEO label highlights skin reactions, infusion reactions, infection, immune complications and hazards of subsequent allogeneic transplantation. In a person whose lymphoma already affects the skin, a new rash could reflect disease or a drug reaction and may need further investigation. Provide the last administration date to any transplant team. A single waiting interval should not be presented as a guarantee of safety for everyone. DailyMed: POTELIGEO mogamulizumab prescribing information, February 2026

Check whether an old approval statement remains current

Romidepsin still appears in PTCL studies and reviews, but FDA's withdrawal table records withdrawal of its specified PTCL accelerated-approval indication on July 30, 2021. This is a different statement from its other cutaneous T-cell indications, use in other countries or research activity. Inclusion in an older treatment list does not establish current approval in the same setting. FDA: Withdrawn cancer accelerated approvals, including romidepsin PTCL

For an overseas recommendation, verify jurisdiction, exact entity, previous lines, single-agent or combination use and document date. Trial registration, regulatory approval and hospital supply answer different questions. A clinician can explain the basis for research or off-label treatment when appropriate, but the description should state that basis rather than replace it with a vague claim of international use.

Make responsibility for home treatment explicit

Separate active from discontinued medicines and preserve the reason for discontinuation. This reduces the chance that a new prescriber unknowingly restarts something associated with a severe reaction. When brand names differ between countries, use the generic name and packaging photographs to help reconcile the list. A change of tablet strength requires a fresh check of tablet numbers rather than reliance on the previous box.

Fever, chills, substantial breathlessness, persistent bleeding or confusion requires timely care. NCI explains the infection risks during cancer treatment; temperature logs and symptom diaries do not replace clinical assessment when needed. The responsible clinician should decide which anticancer, preventive or chronic-disease medicines need interruption in an acute situation. Provide the complete list promptly. NCI: Infection and Neutropenia during Cancer Treatment

At review, ask for the next stage in writing: which medicines continue, when tests are due, what should trigger earlier contact, how response is assessed and when the treatment aim will be reconsidered. A plan that can actually be followed at home is more useful than an ever-longer list of potentially available drugs.